{
    "nct_id": "NCT03558139",
    "official_title": "A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy",
    "inclusion_criteria": "* Safety Run-in Cohort: Pathologically confirmed advanced solid tumors.\n* Ovarian Cancer Expansion Cohort: Histologically or cytologically confirmed, epithelial ovarian, fallopian tube, or peritoneal cancer.\n\n  * Checkpoint inhibitor naive participants.\n  * Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy.\n* Adequate performance status. Adequate hematological, liver, and kidney functions.\n* Availability of pre-treatment tumor tissue to evaluate programmed cell death-ligand 1(PD-L1) expression.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Individuals with symptomatic or untreated central nervous system (CNS) metastases.\n* Prior treatment with cluster of differentiation 47 (CD47) or signal regulatory protein alpha (SIRPÎ±) targeting agents.\n* Known active or chronic hepatitis B or C infection or human immunodeficiency virus (HIV).\n* Red blood cell transfusion dependence.\n* Prior organ transplantation requiring immunosuppression or active autoimmune disease.\n* Significant medical diseases and/or history of uncontrolled intercurrent illness or other serious medical condition.\n* Pregnancy or active breast feeding.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}